Fig. 4

Olaparib combined with ML216 has a better effect in decreasing the proliferation and migration of PC3 cells. A PC3 cells with BLM knockdown were treated with increasing concentrations (20–80 μM) of olaparib for 48 h. Cell viability was assessed using the CCK-8 assay. B–D Viability, proliferation, and clonogenicity of PC3 cells were evaluated using the CCK-8, EdU, and clone formation assays, respectively, after treatment with ML216 (5 μM) and olaparib (40 μM), ML216 or olaparib monotherapy, or DMSO. Representative images and quantification are shown. Scale bars: 50 μm. E, F Invasion and migration assays were performed using the transwell and wound scratch assays, respectively, after PC3 cells treatment with ML216 (5 μM) and olaparib (40 μM), ML216 or olaparib monotherapy, or DMSO. Representative images and quantification are shown. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and “ns” indicated no significant difference)